Pfizer Says Results Positive in Rheumatoid Arthritis Study
12 Juin 2019 - 02:58PM
Dow Jones News
By Michael Dabaie
Pfizer Inc. (PFE) said results were positive from a Phase 3b/4
study in adult patients with moderately to severely active
rheumatoid arthritis.
Patients who achieved low disease activity with Xeljanz extended
release 11 mg once daily plus methotrexate after a 24-week
open-label run-in period, were randomized to evaluate the efficacy
and safety of Xeljanz as monotherapy. The study demonstrated
non-inferiority of methotrexate withdrawal with Xeljanz at week 48,
Pfizer said.
The study results will be presented during a late-breaking oral
session at the Annual European Congress of Rheumatology in Madrid
on June 15.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 12, 2019 08:43 ET (12:43 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024